• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

CVS: 4 Approaches to Reduce The Cost Impact of Gene Therapies

by Jasmine Pennic 01/15/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

While the life-changing and life-saving potential of gene therapies is tremendously exciting, finding ways to pay for these treatments is a significant challenge for families and payors. With prices for a single treatment as high as $2 million, many employers are struggling to find ways to offer coverage without bankrupting their health plans, or even their companies. Newly released CVS Health white paper outlines four key approaches that health plans and employers can utilize to reduce the cost impact of gene therapies. The promise of alleviating a significant amount of suffering could mean that gene therapies are cost effective — at the right price point. Gene therapy has shown tremendous promise for people living with genetic disorders. While these life-altering therapies are exciting, they are also come with high price tags, leaving us to ask – how can we pay for these expensive drugs? Defining Gene Therapy Gene therapies use a target gene that expresses protein products at a sufficient level to cure, or at least ameliorate, a disease caused by a genetic defect. So far, the U.S. Food and Drug Administration (FDA) has approved a handful of gene therapies to treat serious diseases that were previously untreatable except through supportive measures. The European Medicines Agency has approved a few more than the FDA — and there are many more in the pipeline. Estimating the precise cost impact of gene therapies is very complicated and challenging. It is unclear how many patients with a particular condition may be treated with a given therapy or exactly how much the treatment will cost. To help plan sponsors estimate the impact of these treatments, CVS analyzed the projected cost in a newly released white paper based on: Publicly available information about therapies in development Likelihood of approval Estimated prevalence of those conditions Lowest estimated cumulative five-year cost impact based on a price of $1 million and 30 percent market penetration Highest estimated cumulative five-year cost impact based on a price of $2 million, and market penetration of 40 percent for ex vivo therapies, and 60 percent for in vivo therapies Today, there is not enough patient follow-up data yet to know whether they will truly be "cures" or if the diseases will eventually return. Even if they are not truly cures that are sustained over a patient’s lifespan, the promise of alleviating a significant amount of suffering could mean that gene therapies are cost effective — at the right price point. As it stands, the huge, initial costs are clouding that promise. Due to the potentially prohibitive costs, some employers are considering excluding ultra-high cost gene therapies from their plan benefit coverage. However, doing so might be short-sighted if the treatments are proven to be as truly effective long-term as they appear to be today. As a result, that can be a tough rationale to accept for plan sponsors facing a large, one-time burst of spending, here and now. To address the cost-access conundrum, CVS Health has developed a four-pronged strategy for health plans and employers to reduce the cost impact impact of gene therapies: Extend the National Medical Excellence (NME) Program Model – Address medical benefit costs associated with gene therapies by expanding NME program model to enable expert care coordination and keep costs in check. Evolve the Role of Specialty Pharmacy – Enable specialty pharmacies to purchase gene therapies directly from manufacturers to reduce cost impact across the drug supply chain. Implement Value-Based Contracting – Tie reimbursement to an expected outcome to minimize risk to payors and provide long-term real-world efficacy data. Create Financial Protection Plans – Minimize risk for smaller companies and organizations by creating new insurance products that ensure access and protect the financial viability of their benefit plan. For more information on approaches to reduce the cost impact of gene therapies, download the full CVS report here.

– While the life-changing and life-saving potential of gene therapies is tremendously exciting, finding ways to pay for these treatments is a significant challenge for families and payors.

– With prices for a single treatment as high as $2 million, many employers are struggling to find ways to offer coverage without bankrupting their health plans, or even their companies.

– Newly released CVS Health white paper outlines four key approaches that health plans and employers can utilize to reduce the cost impact of gene therapies.

The promise of alleviating a significant amount of suffering could mean that gene therapies are cost-effective — at the right price point. Gene therapy has shown tremendous promise for people living with genetic disorders. While these life-altering therapies are exciting, they are also come with high price tags, leaving us to ask – how can we pay for these expensive drugs?

Defining Gene Therapy

Gene therapies use a target gene that expresses protein products at a sufficient level to cure or at least ameliorate, a disease caused by a genetic defect. So far, the U.S. Food and Drug Administration (FDA) has approved a handful of gene therapies to treat serious diseases that were previously untreatable except through supportive measures. The European Medicines Agency has approved a few more than the FDA — and there are many more in the pipeline.

Estimating the precise cost impact of gene therapies is very complicated and challenging. It is unclear how many patients with a particular condition may be treated with a given therapy or exactly how much the treatment will cost.

To help plan sponsors estimate the impact of these treatments, CVS analyzed the projected cost in a newly released white paper based on

– Publicly available information about therapies in development

– Likelihood of approval Estimated prevalence of those conditions

–Lowest estimated cumulative five-year cost impact based on a price of $1 million and 30 percent market penetration

– Highest estimated cumulative five-year cost impact based on a price of $2 million, and market penetration of 40 percent for ex vivo therapies, and 60 percent for in vivo therapies

Today, there is not enough patient follow-up data yet to know whether they will truly be “cures” or if the diseases will eventually return. Even if they are not truly cures that are sustained over a patient’s lifespan, the promise of alleviating a significant amount of suffering could mean that gene therapies are cost-effective — at the right price point.

As it stands, the huge, initial costs are clouding that promise. Due to the potentially prohibitive costs, some employers are considering excluding ultra-high cost gene therapies from their plan benefit coverage. However, doing so might be short-sighted if the treatments are proven to be as truly effective long-term as they appear to be today. As a result, that can be a tough rationale to accept for plan sponsors facing a large, one-time burst of spending, here and now.

To address the cost-access conundrum, CVS Health has developed a four-pronged strategy for health plans and employers to reduce the cost impact of gene therapies:

1. Extend the National Medical Excellence (NME) Program Model – Address medical benefit costs associated with gene therapies by expanding NME program model to enable expert care coordination and keep costs in check. 

2. Evolve the Role of Specialty Pharmacy – Enable specialty pharmacies to purchase gene therapies directly from manufacturers to reduce cost impact across the drug supply chain.

3. Implement Value-Based Contracting – Tie reimbursement to an expected outcome to minimize risk to payors and provide long-term real-world efficacy data.

4. Create Financial Protection Plans – Minimize risk for smaller companies and organizations by creating new insurance products that ensure access and protect the financial viability of their benefit plan.  

For more information on approaches to reduce the cost impact of gene therapies, download the full CVS report here.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |